TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company


Press Release


Feb, 2018

MabSpace Biosciences Announces FDA Approval of IND for MSB2311, a Second Generation PD-L1 Antibody With pH Dependent Antigen Binding and Recycling Property

(BUSINESS WIRE)--MabSpace Biosciences announces on February 16th, 2018 FDA cleared Investigational New Drug (IND) for MSB2311, a humanized programmed death protein-ligand 1 (PD-L1) antibody for the treatment of patients with locally advanced/metastatic solid tumors.


Jan, 2018

HJB Opens R&D Center and GMP Manufacturing Facility to Develop Biologic Medicines Globally

To benefit global patients by accelerating the design and manufacturing of innovative biologics that meet global standards.
HJB, an organization dedicated to expanding global access to important protein therapeutics, today held the grand opening ceremony for its R&D Center and Manufacturing Facility.


Oct, 2017

MabSpace Biosciences Submits Investigational New Drug Application for its Second Generation PD-L1 Antibody With pH-Dependent Antigen Binding Property

(BUSINESS WIRE)--MabSpace Biosciences Co., Ltd., today announced it has filed an IND application to CFDA on September 12th, 2017 for MSB2311, a second-generation PD-L1 antibody with pH-dependent antigen binding property.


Mar, 2017

HJB and G-CON Manufacturing Announce Collaboration on State of the Art Bioprocess Facility in China

HJB and G-CON Manufacturing today announced that the companies are working together on HJB’s state of the art biologics facility in the Hangzhou Economic & Technology Development Area (HEDA) in China.


Feb, 2017

MabSpace Biosciences to Present Preclinical Data on Second Generation PD-L1 Antibody with pH-Dependent Antigen Binding Property at Upcoming Inaugural ASCO-SITC Clinical Immuno-Oncology Symposium

(BUSINESS WIRE)--Suzhou-based MabSpace Biosciences announced that the preclinical data for its lead program MSB2311, a 2nd generation humanized PD-L1 blocking antibody with a unique pH-dependent antigen binding property, will be presented at the upcoming 2017 Inaugural American Society of Clinical Oncology (ASCO)-Society for Immunotherapy of Cancer (SITC) Annual Meeting on February 23rd-25th, 2017 in Orlando, Florida, US.


Jan, 2017

Ambrx and MabSpace Biosciences to Collaborate on Novel Antibody Drug Conjugates

(BUSINESS WIRE)--San Diego based Ambrx Inc. and Suzhou based MabSpace Biosciences have agreed to collaborate on discovery and development of multiple novel ADCs in China and around the world for oncology.

1... 5 6 7 8 9